Prostate Cancer

Researchers have determined that patients who received sipuleucel-T (Provenge, Dendreon) developed immune parameters that correlate to improved overall survival, giving researchers a better understanding of how the immunotherapy works at a cellular level to improve survival.

The novel drug enzalutamide (formerly MDV3100) significantly improved overall survival in men with metastatic castrate-resistant prostate cancer (mCRPC).

Dr. Charles Ryan from the UCSF Helen Diller Family Comprehensive Cancer Center Discusses the Unblinding of the COU-AA-302 Trial

Men with a baseline PSA between 1.5 and 4.0 ng/mL faced a 15-fold increase in prostate cancer over a four-year period as compared with men whose baseline PSA levels were

An interim analysis of the COU-AA-302 trial investigating the use of abiraterone acetate (Zytiga) in chemotherapy-naïve patients with mCRPC showed a trend toward improvement in PFS and OS.

Since the phase III AFFIRM trial of enzalutamide was halted after meeting its endpoint of improved OS, physicians have remained hopeful about its potential as a treatment for prostate cancer.

The novel agent OGX-427 delayed disease progression in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer, according to the preliminary results.

Research presented at ASCO 2012 examined the expanded use of sipuleucel-T, as well as methods to determine which patients might benefit the most from the therapy.

Preliminary data suggest a promising role for sipuleucel-T as a treatment for African-American men with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Mary-Ellen Taplin, from the Dana-Farber Cancer Institute, on Abiraterone Acetate's Mechanism of Action

Patients with prostate cancer can expect better sexual function after a robotic-assisted radical prostatectomy (RARP) if they maintain a healthy lifestyle.

In tough economic times when many medical practices have scaled back or even shut down, The Urology Group has flourished.

Spurred by the desire to provide the full spectrum of care to prostate cancer patients, urologists across the country have begun to integrate bone health clinics into their practices.